Science
Sara Elena Rebuzzi։ Using AI to Predict Immunotherapy Outcomes in Metastatic Renal Cell Carcinoma
Sara Elena Rebuzzi/LinkedIn

Sara Elena Rebuzzi։ Using AI to Predict Immunotherapy Outcomes in Metastatic Renal Cell Carcinoma

Sara Elena Rebuzzi, Medical Oncologist, MD, PhD at A.O.U. Città della Salute e della Scienza di Torino, shared on LinkedIn:

“Great collaboration on the use of Artificial Intelligence for assessing prognostic biomarkers in mRCC patients receiving immunotherapy.

This work provides a solid foundation for our upcoming research in the first-line setting. Looking forward to the next steps!”

Title: Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma – Meet-URO 15-AI study

Authors: Sara Elena Rebuzzi, Vanja Miskovic, Giuseppe Fornarini, Sara Ferri, Sebastiano Buti, Matteo Piceni, Alessio Signori, Leonardo Provenzano, Giuseppe Luigi Banna, Pasquale Rescigno, Marco Maruzzo, Davide Bimbatti, Beatrice Ramella Pollone, Umberto Basso, Ugo De Giorgi, Paolo Pedrazzoli, Luca Galli, Paolo Andrea Zucali, Fabrizio Di Costanzo, Aruni Ghose, Alessandra Laura Giulia Pedrocchi, Arsela Prelaj

Read the article

Other articles about AI and Renal Cell Carcinoma on OncoDaily.

Alessandra Laura Giulia Pedrocchi Alessio Signori Arsela Prelaj artificial intelligence Aruni Ghose Beatrice Ramella Pollone cancer Davide Bimbatti Fabrizio Di Costanzo Giuseppe Banna Giuseppe Fornarini Giuseppe Luigi Banna immunotherapy Leonardo Provenzano Luca Galli Marco Maruzzo Matteo Piceni OncoDaily Oncology Paolo Andrea Zucali Paolo Pedrazzoli Pasquale Rescigno Sara Elena Rebuzzi Sara Ferri Sebastiano Buti Ugo de Giorgi Umberto Basso Vanja Mišković